SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets nod to transfer generics business undertaking

06 Nov 2023 Evaluate

Cipla has received approval from board of directors to transfer Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences (CPLS), a wholly owned subsidiary of the Company. Effective date for completion of transfer to CPLS would be end of business hours of December 31, 2023, or such other date mutually agreed between the parties. The consideration to be received from such sale will be Rs 350 crore. The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×